文献速递乳腺癌放疗

绝经前女性低分割全乳放疗联合术中电子线推量的十年结果

Ten-year results of hypofractionated whole breast radiotherapy and intraoperative electron boost in premenopausal women.
PubMed 文献 · Radiother Oncol · 2022-10-28

该研究分析了481例≤48岁pT1-2 N0-1乳腺癌患者接受12 Gy术中电子线推量联合三维适形低分割全乳放疗(13次,2.85 Gy/次)的十年结局。中位随访9.6年,十年局部复发累积发生率4.1%,十年无病生存率80.0%、乳腺癌特异生存率97.5%、总生存率96.5%。作者认为该方案局部控制优异但以瘤床纤维化为代价,并建议术中电子线推量剂量低于12 Gy。

要点

  • 481例≤48岁乳腺癌患者接受12 Gy术中电子线推量联合低分割全乳放疗,中位随访9.6年。
  • 十年局部复发累积发生率4.1%(95%CI 2.5-6.3),23例局部复发中9例位于推量区域。
  • 中重度纤维化发生率为40.8%,美容效果优良率为86%。

核心结论

  • 术中电子线推量联合低分割全乳放疗在年轻乳腺癌患者中获得了优异的局部控制,但代价是瘤床纤维化。
  • 作者认为术中电子线推量剂量低于12 Gy是可取的。

研究设计与样本

  • 研究纳入2004年至2014年间接受保乳手术的481例连续乳腺癌患者,年龄≤48岁,pT1-2 N0-1。
  • 患者术中接受12 Gy术中电子线推量,术后接受三维适形低分割全乳放疗13次(2.85 Gy/次)。
  • 分析局部复发和无病生存、乳腺癌特异生存、总生存等生存结局。

主要发现

  • 中位肿瘤大小1.48 cm,中位术中电子线准直器尺寸4 cm,中位年龄42岁,多数为淋巴结阴性。
  • 中位随访9.6年,共23例局部复发(4.8%),其中9例位于推量区域。
  • 十年局部复发累积发生率为4.1%(95%CI 2.5-6.3)。
  • 十年无病生存率为80.0%(95%CI 75.8-83.5),乳腺癌特异生存率为97.5%(95%CI 95.5-98.6),总生存率为96.5%(95%CI 94.3-97.9)。
  • 围手术期并发症发生率为16.4%,急性毒性轻微(3级<2%),中重度纤维化发生率为40.8%,美容效果优良率为86%。

关键数值与推荐

  • 多因素分析显示局部复发预测因素包括年龄<40岁、广泛导管内成分和使用4 cm术中电子线准直器尺寸。
  • 随时间推移,Luminal A型和激素受体阴性的HER2阳性患者局部控制率下降,而三阴性患者保持稳定。
  • Luminal B HER2阴性患者生存结局最差。

临床怎么用

  • 作者认为术中电子线推量剂量低于12 Gy是可取的,但原文未据此给出具体推荐等级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate outcome of intraoperative electron boost (IOERT) and hypofractionated whole breast irradiation (HWBI) for breast cancer (BC) in young women. METHODS AND MATERIALS: Women aged ≤ 48 with pT1-2 N0-1 BC received 12 Gy IOERT boost during conservative surgery followed by 3-dimensional conformal HWBI in 13 fractions (2.85 Gy/die). Local relapses (LR) and survival (disease-free, DFS; specific, BCSS; overall, OS) were analyzed. RESULTS: 481 consecutive BC patients, mostly node negative, with median age of 42 were treated between 2004 and 2014. Median tumor size was 1.48 cm and median IOERT collimator was 4 cm. After 25-day mean interval, HWBI was delivered. At a median follow-up of 9.6 years, there were 23 LRs (4.8 %, 9 of which were in the boost region). Ten-year LR cumulative incidence was 4.1 % (95 %CI, 2.5-6.3). Over time, local control rate decreased for Luminal A and HER2 positive with negative hormonal receptors, while remained steady for triple negative. At multivariate analysis, LR predictors included age < 40, extensive intraductal component and the use of 4-cm IOERT collimator size. Ten-year survival outcomes were as follows: DFS 80.0 % (95 % CI, 75.8-83.5), BCSS 97.5 % (95 % CI, 95.5-98.6 %), OS 96.5 % (95 % CI, 94.3-97.9). Luminal B HER2 negative had the worse survival outcomes. Perioperative complications were uncommon (16.4 %), acute toxicity was mild (<2% Grade 3), but moderate/severe fibrosis was described in 40.8 % of the cases. Cosmesis was scored as excellent/good in 86 % of the cases. CONCLUSIONS: ELIOT boost and HWBI achieved an excellent local control at the cost of tumor bed fibrosis. IOERT boost dose lower than 12 Gy is advisable.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Leonardi MC, Cormio CF, Frassoni S, et al. Ten-year results of hypofractionated whole breast radiotherapy and intraoperative electron boost in premenopausal women. Radiother Oncol. 2022. PMID: 36377094. doi:10.1016/j.radonc.2022.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。